Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings

01/02/25 • 0 min

Host: Jacob Sands, MD
Guest: Julia Rotow, MD

In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, the standard second-line therapy is docetaxel, but this can have poor response rates. That’s why the DESTINY-Lung03 trial examined the safety and efficacy of trastuzumab deruxtecan in patients with pretreated HER2-overexpressing non-squamous NSCLC. Here with Dr. Jacob Sands to share the findings from part 1 of this trial is thoracic medical oncologist Dr. Julia Rotow.

Host: Jacob Sands, MD
Guest: Julia Rotow, MD

Previous Episode

Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Laura Alder, MD

The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and substantial toxicity. But given the complex structure of ADCs, it’s important to identify biomarkers that can predict a patient’s response to therapy. That’s why the phase 1b TROPION-LUNG02 trial examined the effectiveness of Dato-DXd and HER3-DXd in the presence of predictive biomarkers. Joining Dr. Charles Turck to discuss the trial’s findings and implications is Dr. Laura Alder, Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina.

Next Episode

Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Paolo Tarantino, MD

Sacituzumab govitecan is a TROP-2 antibody drug conjugate approved for patients with metastatic triple-negative breast cancer (mTNBC) based on findings from the ASCENT study. But how is this treatment approach performing in the real world? Joining Dr. Charles Turck to share a study’s findings on the real-world efficacy and safety of sacituzumab govitecan is Dr. Paolo Tarantino, medical oncologist and advanced research fellow in the Breast Oncology Program at Dana-Farber Cancer Institute and Harvard Medical School.